Tumor Biology

, Volume 37, Issue 1, pp 897–903 | Cite as

Prognostic value of long non-coding RNA MALAT1 in cancer patients

Original Article

Abstract

Metastasis associated in lung adenocarcinoma transcript 1 (MALAT1) was identified to be the first long non-coding RNA as a biomarker of independent prognostic value for early stage non-small cell lung cancer patient survival. In recent years, the association between upregulated tissue MALAT1 level and incidence of various cancers including bladder cancer, colorectal cancer, and renal cancer has been widely discussed. The aim of our present study was to assess the potential prognostic value of MALAT1 in various human cancers. PubMed, Embase, Ovid, and Cochrane Library databases were systematically searched, and eligible studies evaluating the prognostic value of MALAT1 in various cancers were included. Finally, 11 studies encompassing 1216 participants reporting with sufficient data were enrolled in the current meta-analysis. The pooled hazard ratio (HR) was 2.05 (95 % confidence interval (CI) 1.64–2.55, p < 0.01) for overall survival (OS) and 2.66 (95 % CI 1.86–3.80, p < 0.01) for disease-free survival (DFS). In conclusion, high tissue MALAT1 level was associated with an inferior clinical outcome in various cancers, suggesting that MALAT1 might serve as a potential prognostic biomarker for various cancers.

Keywords

Metastasis associated in lung adenocarcinoma transcript 1 (MALAT1) Cancer Prognostic value 

Notes

Acknowledgments

The work was funded by the National Natural Science Foundation of China (Grant nos. 31471297, 81302455, 81201557, 81373036).

Conflicts of interest

None.

Author’s contributions

YW and DX have the right to grant on behalf of all authors and does grant on behalf of all authors. YW and WL contributed to conception and design of the study; WL, JX, and HZ contributed to conception, design, and editing the manuscript. All authors commented on drafts of the paper and have approved the final draft of the manuscript.

References

  1. 1.
    Birney E, Stamatoyannopoulos JA, Dutta A, Guigo R, Gingeras TR, Margulies EH, et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature. 2007;447(7146):799–816. doi: 10.1038/nature05874.CrossRefPubMedGoogle Scholar
  2. 2.
    Costa FF. Non-coding RNAs: meet thy masters. Bioessays. 2010;32(7):599–608. doi: 10.1002/bies.200900112.CrossRefPubMedGoogle Scholar
  3. 3.
    Struhl K. Transcriptional noise and the fidelity of initiation by RNA polymerase II. Nat Struct Mol Biol. 2007;14(2):103–5. doi: 10.1038/nsmb0207-103.CrossRefPubMedGoogle Scholar
  4. 4.
    Ebisuya M, Yamamoto T, Nakajima M, Nishida E. Ripples from neighbouring transcription. Nat Cell Biol. 2008;10(9):1106–13. doi: 10.1038/ncb1771.CrossRefPubMedGoogle Scholar
  5. 5.
    Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10(3):155–9. doi: 10.1038/nrg2521.CrossRefPubMedGoogle Scholar
  6. 6.
    Perez DS, Hoage TR, Pritchett JR, Ducharme-Smith AL, Halling ML, Ganapathiraju SC, et al. Long, abundantly expressed non-coding transcripts are altered in cancer. Hum Mol Genet. 2008;17(5):642–55. doi: 10.1093/hmg/ddm336.CrossRefPubMedGoogle Scholar
  7. 7.
    Tripathi V, Ellis JD, Shen Z, Song DY, Pan Q, Watt AT, et al. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell. 2010;39(6):925–38. doi: 10.1016/j.molcel.2010.08.011.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Wilusz JE, Freier SM, Spector DL. 3’ end processing of a long nuclear-retained noncoding RNA yields a tRNA-like cytoplasmic RNA. Cell. 2008;135(5):919–32. doi: 10.1016/j.cell.2008.10.012.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Ji P, Diederichs S, Wang W, Boing S, Metzger R, Schneider PM, et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene. 2003;22(39):8031–41. doi: 10.1038/sj.onc.1206928.CrossRefPubMedGoogle Scholar
  10. 10.
    Gutschner T, Hammerle M, Eissmann M, Hsu J, Kim Y, Hung G, et al. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res. 2013;73(3):1180–9. doi: 10.1158/0008-5472.can-12-2850.CrossRefPubMedGoogle Scholar
  11. 11.
    Hutchinson JN, Ensminger AW, Clemson CM, Lynch CR, Lawrence JB, Chess A. A screen for nuclear transcripts identifies two linked noncoding RNAs associated with SC35 splicing domains. BMC Genomics. 2007;8:39. doi: 10.1186/1471-2164-8-39.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Lin R, Maeda S, Liu C, Karin M, Edgington TS. A large noncoding RNA is a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas. Oncogene. 2007;26(6):851–8. doi: 10.1038/sj.onc.1209846.CrossRefPubMedGoogle Scholar
  13. 13.
    Yang MH, Hu ZY, Xu C, Xie LY, Wang XY, Chen SY, et al. MALAT1 promotes colorectal cancer cell proliferation/migration/invasion via PRKA kinase anchor protein 9. Biochim Biophys Acta. 2015;1852(1):166–74. doi: 10.1016/j.bbadis.2014.11.013.CrossRefPubMedGoogle Scholar
  14. 14.
    Wu XS, Wang XA, Wu WG, Hu YP, Li ML, Ding Q, et al. MALAT1 promotes the proliferation and metastasis of gallbladder cancer cells by activating the ERK/MAPK pathway. Cancer Biol Ther. 2014;15(6):806–14. doi: 10.4161/cbt.28584.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Wang J, Su L, Chen X, Li P, Cai Q, Yu B, et al. MALAT1 promotes cell proliferation in gastric cancer by recruiting SF2/ASF. Biomed Pharmacother. 2014;68(5):557–64. doi: 10.1016/j.biopha.2014.04.007.CrossRefPubMedGoogle Scholar
  16. 16.
    Ying L, Chen Q, Wang Y, Zhou Z, Huang Y, Qiu F. Upregulated MALAT-1 contributes to bladder cancer cell migration by inducing epithelial-to-mesenchymal transition. Mol Biosyst. 2012;8(9):2289–94. doi: 10.1039/c2mb25070e.CrossRefPubMedGoogle Scholar
  17. 17.
    Tano K, Akimitsu N. Long non-coding RNAs in cancer progression. Front Genet. 2012;3:219. doi: 10.3389/fgene.2012.00219.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336–41. doi: 10.1016/j.ijsu.2010.02.007.CrossRefPubMedGoogle Scholar
  19. 19.
    Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9. doi: 10.1186/1471-2288-12-9.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Lai MC, Yang Z, Zhou L, Zhu QQ, Xie HY, Zhang F, et al. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. Med Oncol. 2012;29(3):1810–6. doi: 10.1007/s12032-011-0004-z.CrossRefPubMedGoogle Scholar
  21. 21.
    Liu JH, Chen G, Dang YW, Li CJ, Luo DZ. Expression and prognostic significance of lncRNA MALAT1 in pancreatic cancer tissues. Asian Pac J Cancer Prev. 2014;15(7):2971–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Ma KX, Wang HJ, Li XR, Li T, Su G, Yang P et al. Long noncoding RNA MALAT1 associates with the malignant status and poor prognosis in glioma. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2015. doi: 10.1007/s13277-014-2969-7
  23. 23.
    Okugawa Y, Toiyama Y, Hur K, Toden S, Saigusa S, Tanaka K, et al. Metastasis-associated long non-coding RNA drives gastric cancer development and promotes peritoneal metastasis. Carcinogenesis. 2014;35(12):2731–9. doi: 10.1093/carcin/bgu200.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Pang EJ, Yang R, Fu XB, Liu YF. Overexpression of long non-coding RNA MALAT1 is correlated with clinical progression and unfavorable prognosis in pancreatic cancer. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014. doi: 10.1007/s13277-014-2850-8
  25. 25.
    Schmidt LH, Spieker T, Koschmieder S, Schaffers S, Humberg J, Jungen D, et al. The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. J Thorac Oncol. 2011;6(12):1984–92. doi: 10.1097/JTO.0b013e3182307eac.CrossRefPubMedGoogle Scholar
  26. 26.
    Shen L, Chen L, Wang Y, Jiang X, Xia H, Zhuang Z. Long noncoding RNA MALAT1 promotes brain metastasis by inducing epithelial-mesenchymal transition in lung cancer. J Neurooncol. 2015;121(1):101–8. doi: 10.1007/s11060-014-1613-0.CrossRefPubMedGoogle Scholar
  27. 27.
    Zhang HM, Yang FQ, Chen SJ, Che J, Zheng JH. Upregulation of long non-coding RNA MALAT1 correlates with tumor progression and poor prognosis in clear cell renal cell carcinoma. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014. doi: 10.1007/s13277-014-2925-6
  28. 28.
    Zheng HT, Shi DB, Wang YW, Li XX, Xu Y, Tripathi P, et al. High expression of lncRNA MALAT1 suggests a biomarker of poor prognosis in colorectal cancer. Int J Clin Exp Pathol. 2014;7(6):3174–81.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Fan Y, Shen B, Tan M, Mu X, Qin Y, Zhang F, et al. TGF-beta-induced upregulation of MALAT1 promotes bladder cancer metastasis by associating with suz12. Clin Cancer Res. 2014;20(6):1531–41. doi: 10.1158/1078-0432.ccr-13-1455.CrossRefPubMedGoogle Scholar
  30. 30.
    Weber DG, Johnen G, Casjens S, Bryk O, Pesch B, Jockel KH, et al. Evaluation of long noncoding RNA MALAT1 as a candidate blood-based biomarker for the diagnosis of non-small cell lung cancer. BMC Res Notes. 2013;6:518. doi: 10.1186/1756-0500-6-518.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Jiao F, Hu H, Yuan C, Wang L, Jiang W, Jin Z, et al. Elevated expression level of long noncoding RNA MALAT-1 facilitates cell growth, migration and invasion in pancreatic cancer. Oncol Rep. 2014;32(6):2485–92.PubMedGoogle Scholar
  32. 32.
    Li S, Wang Q, Qiang Q, Shan H, Shi M, Chen B et al. Sp1-mediated transcriptional regulation of MALAT1 plays a critical role in tumor. Journal of cancer research and clinical oncology. 2015. doi: 10.1007/s00432-015-1951-0
  33. 33.
    Wang X, Li M, Wang Z, Han S, Tang X, Ge Y et al. Silencing of long noncoding RNA MALAT1 by miR-101 and miR-217inhibits proliferation, migration and invasion of esophageal squamous cell carcinoma cells. The Journal of biological chemistry. 2014. doi: 10.1074/jbc.M114.596866
  34. 34.
    Ji Q, Liu X, Fu X, Zhang L, Sui H, Zhou L, et al. Resveratrol inhibits invasion and metastasis of colorectal cancer cells via MALAT1 mediated Wnt/beta-catenin signal pathway. PloS one. 2013;8(11):e78700. doi: 10.1371/journal.pone.0078700.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of Toxicology, School of Public HealthZhejiang UniversityHangzhouPeople’s Republic of China
  2. 2.Department of Epidemiology and Health Statistics, School of Public HealthZhejiang UniversityHangzhouPeople’s Republic of China
  3. 3.State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, First Affiliated HospitalZhejiang University School of MedicineHangzhouPeople’s Republic of China
  4. 4.Department of Pathology, Medical SchoolZhejiang UniversityHangzhouPeople’s Republic of China

Personalised recommendations